NASDAQ:BLU (Bellus Health)
About BLU
BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.
Financial Market Data copyright © 2024
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Profiles by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Financials by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2024
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Share Information by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Dividends by EDI/Mergent (USA) and TSX (CDN).
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Earnings and Analyst Ratings by Zacks.
Earnings Events by Wall Street Horizon.
Terms of Use.